Equillium posts new preclinical EQ504 data in ulcerative colitis at International AHR Conference
Bitget2026/09/29 20:05- Equillium disclosed new preclinical findings for EQ504 in ulcerative colitis ahead of two poster presentations at the 7th International AHR Conference.
- Results will be presented September 29 to October 2, 2026, in Porto, Portugal.
- Data point to improved intestinal barrier repair with reduced inflammatory signaling, supporting EQ504’s therapeutic rationale in ulcerative colitis.
- Separate work indicates immune rebalancing, with suppression of pro-inflammatory responses alongside enhancement of regulatory pathways linked to tissue repair.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
